STOCKS TELEGRAPH

Tag: BIVI Stock

  • Angel Oak (AOMR) Stock Climbs In After-Market After Financial Results News

    Angel Oak (AOMR) Stock Climbs In After-Market After Financial Results News

    Angel Oak Mortgage REIT, Inc. (NYSE: AOMR) stock has moved significantly since the company’s impending financial results were revealed. After a calm trading day that closed at $9.79, down -0.51%, AOMR shares increased 4.19% to $10.20 in last Friday’s after-market session.

    The company will release its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, before to the market opening. A conference call to discuss the performance will be place later that day.

    Successful Residential Mortgage Loan Securitization

    Angel Oak (AOMR) recently announced its financial accomplishments and completed a large securitization, AOMT 2024-10, valued at around $317 million. A pool of residential mortgage loans serves as the collateral for this securitization, and Fitch Ratings has given the senior tranche a AAA rating. The successful completion of AOMT 2024-10 demonstrates the robustness of Angel Oak’s business strategy by highlighting its efficient platforms for origination, acquisition, and securitization.

    Strategic Capital Deployment and Future Growth

    Angel Oak’s second quarter discussions indicated that the loans involved in the AOMT 2024-10 securitization were primarily funded through proceeds from the company’s July senior unsecured notes issuance. By effectively deploying this capital, Angel Oak has managed to cover the cost of capital from its July offering and set the foundation for growth in the fourth quarter and beyond.

    AOMR plans to reinvest the capital from this securitization into newly originated, high-quality non-QM (non-qualified mortgage) loans, further enhancing its balance sheet growth and net interest margin.

    Impact of Securitization on Debt and Funding Costs

    AOMT 2024-10 includes a portfolio of 661 non-QM loans, amounting to $316.8 million in principal balance, with a weighted average loan coupon of 7.79%. The deal lowers the funding cost for these loans by more than 110 basis points, further supported by the Federal Reserve’s recent rate cuts. Additionally, this transaction reduces Angel Oak’s whole loan warehouse debt by $260 million, significantly improving the company’s debt-to-equity ratio.

  • BioVie (BIVI) Stock Surges After Hours Following Major Regulatory Milestone

    BioVie (BIVI) Stock Surges After Hours Following Major Regulatory Milestone

    Shares of BioVie Inc. (NASDAQ: BIVI) experienced a remarkable surge in trading last Friday, with stock prices climbing by an impressive 109.82% during regular session to close at $2.35.

    This upward trajectory continued into the extended session, where BIVI stock gained an additional 9.77%, reaching $2.58. This significant increase in value is attributed to a pivotal regulatory milestone achieved by the company in Japan.

    Regulatory Achievement

    BioVie (BIVI) declared late last week that the Japan Patent Office had granted it a Notice of Allowance for patent application number 2021-569344, which is entitled “Formulations of Terlipressin.”

    After administrative procedures are finished, it is expected that this Notice of Allowance will result in the issuing of a Japanese patent in the following two to three weeks. The authorized claims relate to a new liquid version of terlipressin acetate that is easily packed in a pre-filled syringe and has a two-year shelf life at room temperature.

    Taking Care of Medical Needs

    The goal of BioVie’s novel formulation is to develop a more patient-centered ambulatory treatment plan for Americans with hepatic failure and ascites. The prognosis for those who develop refractory ascites is difficult; their one-year survival rate is just about 50%. Currently, there is no approved therapy specifically targeting refractory ascites, leaving management reliant on temporary procedures that do not offer lasting solutions.

    Enhanced Treatment Potential

    Terlipressin is a well-established drug utilized in over 40 countries for treating complications related to liver cirrhosis. It has recently gained approval in the United States, albeit as a lyophilized powder requiring reconstitution and refrigeration.

    BioVie’s liquid formulation presents a significant advancement, providing stability at room temperature for 24 months. This feature, combined with the pre-filled syringe format, enhances dosing convenience and safety, particularly in home-care settings.

    Furthermore, the receipt of this patent will fortify BioVie’s intellectual property protections, thereby bolstering the value proposition of its BIV201 program. In addition to the recent approvals in the US and Japan, BioVie (BIVI) holds patent protections for its liquid formulation in India and Chile, with additional patents pending globally.

  • BioVie Inc. (BIVI) Sees Stock Movement After Pricing News

    BioVie Inc. (NASDAQ: BIVI) had a wild ride last Friday, with its stock price shooting up by an impressive 52.4%. However, this was short-lived as the company experienced a significant downturn over the weekend, plummeting by nearly 44% by Monday morning’s premarket trading.

    This sudden swing in fortunes caught the attention of investors, especially given the surge in trading volume, which reached almost 93 million shares.

    Exploring BioVie Inc.

    BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company dedicated to developing innovative drug therapies for neurological and neurodegenerative disorders, as well as advanced liver disease. One of its key drug candidates, NE3107, has shown promise in inhibiting inflammatory activation associated with diseases like Alzheimer’s and Parkinson’s.

    Recent studies have revealed positive outcomes, including improved cognition and biomarker levels in Alzheimer’s patients treated with NE3107. Moreover, NE3107 in combination with levodopa has demonstrated significant improvements in motor control for Parkinson’s patients without any notable adverse effects.

    When it comes to liver disease, BioVie Inc. is advancing BIV201, an orphan drug candidate with FDA Fast Track status, for treating ascites due to chronic liver cirrhosis. With its active agent approved in multiple countries for related complications of advanced liver cirrhosis, BIV201 holds significant promise in addressing unmet medical needs in this domain.

    Public Offering Pricing Announcement

    The recent turbulence in BioVie Inc.’s stock price coincided with the company’s announcement of pricing for its public offering. BioVie disclosed the pricing of a best efforts public offering, comprising 21,000,000 shares of its common stock, and warrants to purchase up to 10,500,000 shares at a combined offering price of $1.00 per share.

    Additionally, the associated warrants will have an exercise price of $1.50 per share and will be immediately exercisable for a period of five years following issuance. The expected gross proceeds from this offering amount to approximately $21 million, with the company intending to utilize the net proceeds primarily for working capital and general corporate purposes.

    Conclusion

    The recent fluctuations in BioVie Inc.’s stock price following the public offering announcement underscore the market’s interest in the company’s innovative drug pipeline. With promising developments in treating neurological disorders and advanced liver disease, investors are closely monitoring BioVie’s progress as it navigates the next phase of its growth and development.